GlassScriptPhysician profile
Venkat Chitumalla
NPI 1750585113
$3,765.56
in general payments reported to CMS, 2019-2025
27 companies · $855 in 2025
The $855 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $660 · 2020: $171 · 2021: $253 · 2022: $346 · 2023: $781 · 2024: $699 · 2025: $855.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,252 · Education: $82.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,252.27 |
| Education | $82.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $494.68 | 2019-2025 | Lokelma, Farxiga |
| Amgen INC. | $421.47 | 2019-2025 | Krystexxa, Tavneos |
| Mallinckrodt Hospital Products INC. | $359.84 | 2020-2025 | Terlivaz, Acthar |
| Mallinckrodt Enterprises LLC | $327.29 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $273.24 | 2022-2025 | |
| Vifor Pharma, INC. | $257.85 | 2019-2025 | Veltassa |
| Stryker Corporation | $253.05 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $239.63 | 2019-2025 | Jynarque |
| Novartis Pharmaceuticals Corporation | $231.19 | 2023-2025 | |
| Calliditas Therapeutics US INC. | $123.78 | 2023-2025 | Tarpeyo |
| Ardelyx, INC. | $123.06 | 2024-2025 | Ibsrela |
| Travere Therapeutics, INC. | $94.66 | 2022-2025 | Filspari |
| Horizon Therapeutics Plc | $84.84 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $71.46 | 2024-2025 | Purified Cortrophin Gel |
| Alexion Pharmaceuticals, INC. | $66.54 | 2023-2025 | Ultomiris |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $64.44 | 2019-2023 | Rayaldee |
| Aurinia Pharma U.S., INC. | $44.29 | 2024-2025 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.12 | 2025 | Jardiance |
| Baxter Healthcare | $40.17 | 2020 | |
| Kyowa Kirin, INC. | $29.19 | 2023 | Crysvita |
| Recor Medical INC | $24.35 | 2024 | Paradise Renal Denervation System |
| Genzyme Corporation | $22.48 | 2019 | |
| Fresenius USA Marketing, INC. | $20.64 | 2023 | Velphoro, Korsuva |
| Renalytix Ai, INC. | $16.41 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Janssen Pharmaceuticals, INC | $13.87 | 2019 | |
| Merck Sharp & Dohme LLC | $12.43 | 2019 | |
| Allergan, INC. | $11.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Venkat Chitumalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.